1. BMC Biol. 2020 Jan 23;18(1):9. doi: 10.1186/s12915-020-0739-0.

Control of glutamate release by complexes of adenosine and cannabinoid 
receptors.

Köfalvi A(1), Moreno E(2), Cordomí A(3), Cai NS(4), Fernández-Dueñas V(5)(6), 
Ferreira SG(1), Guixà-González R(3), Sánchez-Soto M(4), Yano H(4), 
Casadó-Anguera V(2), Cunha RA(1)(7), Sebastião AM(8)(9), Ciruela F(10)(11), 
Pardo L(12), Casadó V(13), Ferré S(14).

Author information:
(1)CNC-Center for Neuroscience and Cell Biology, University of Coimbra, 
3004-504, Coimbra, Portugal.
(2)Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, and 
Institute of Biomedicine, University of Barcelona, 08028, Barcelona, Spain.
(3)Laboratori de Medicina Computacional, Unitat de Bioestadística, Facultat de 
Medicina, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain.
(4)Integrative Neurobiology Section, National Institute on Drug Abuse, 
Intramural Research Program, National Institutes of Health, Baltimore, MD, 
21224, USA.
(5)Unitat de Farmacologia, Departament Patologia i Terapèutica Experimental, 
Facultat de Medicina, IDIBELL, Universitat de Barcelona, L'Hospitalet de 
Llobregat, Spain.
(6)Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain.
(7)Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
(8)Instituto de Farmacologia e Neurociências, Faculdade de Medicina, 
Universidade de Lisboa, Lisbon, Portugal.
(9)Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de 
Lisboa, Lisbon, Portugal.
(10)Unitat de Farmacologia, Departament Patologia i Terapèutica Experimental, 
Facultat de Medicina, IDIBELL, Universitat de Barcelona, L'Hospitalet de 
Llobregat, Spain. Fciruela@ub.edu.
(11)Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain. 
Fciruela@ub.edu.
(12)Laboratori de Medicina Computacional, Unitat de Bioestadística, Facultat de 
Medicina, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain. 
Leonardo.Pardo@uab.es.
(13)Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, 
and Institute of Biomedicine, University of Barcelona, 08028, Barcelona, Spain. 
vcasado@ub.edu.
(14)Integrative Neurobiology Section, National Institute on Drug Abuse, 
Intramural Research Program, National Institutes of Health, Baltimore, MD, 
21224, USA. sferre@intra.nida.nih.gov.

BACKGROUND: It has been hypothesized that heteromers of adenosine A2A receptors 
(A2AR) and cannabinoid CB1 receptors (CB1R) localized in glutamatergic nerve 
terminals mediate the integration of adenosine and endocannabinoid signaling 
involved in the modulation of striatal excitatory neurotransmission. Previous 
studies have demonstrated the existence of A2AR-CB1R heteromers in artificial 
cell systems. A dependence of A2AR signaling for the Gi protein-mediated CB1R 
signaling was described as one of its main biochemical characteristics. However, 
recent studies have questioned the localization of functionally significant 
A2AR-CB1R heteromers in striatal glutamatergic terminals.
RESULTS: Using a peptide-interfering approach combined with biophysical and 
biochemical techniques in mammalian transfected cells and computational 
modeling, we could establish a tetrameric quaternary structure of the A2AR-CB1R 
heterotetramer. This quaternary structure was different to the also tetrameric 
structure of heteromers of A2AR with adenosine A1 receptors or dopamine D2 
receptors, with different heteromeric or homomeric interfaces. The specific 
quaternary structure of the A2A-CB1R, which depended on intermolecular 
interactions involving the long C-terminus of the A2AR, determined a significant 
A2AR and Gs protein-mediated constitutive activation of adenylyl cyclase. Using 
heteromer-interfering peptides in experiments with striatal glutamatergic 
terminals, we could then demonstrate the presence of functionally significant 
A2AR-CB1R heteromers with the same biochemical characteristics of those studied 
in mammalian transfected cells. First, either an A2AR agonist or an A2AR 
antagonist allosterically counteracted Gi-mediated CB1R agonist-induced 
inhibition of depolarization-induced glutamate release. Second, co-application 
of both an A2AR agonist and an antagonist cancelled each other effects. Finally, 
a CB1R agonist inhibited glutamate release dependent on a constitutive 
activation of A2AR by a canonical Gs-Gi antagonistic interaction at the adenylyl 
cyclase level.
CONCLUSIONS: We demonstrate that the well-established cannabinoid-induced 
inhibition of striatal glutamate release can mostly be explained by a 
CB1R-mediated counteraction of the A2AR-mediated constitutive activation of 
adenylyl cyclase in the A2AR-CB1R heteromer.

DOI: 10.1186/s12915-020-0739-0
PMCID: PMC6979073
PMID: 31973708 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare that they have no competing 
interests.